Jade Biosciences is a clinical-stage biotechnology company focused on developing best-in-class therapies that address critical unmet needs in autoimmune diseases. Jade’s lead candidate, JADE101, targets the cytokine APRIL, and is currently being evaluated for the treatment of immunoglobulin A nephropathy. Jade’s pipeline also includes JADE201, an afucosylated anti-BAFF-R monoclonal antibody, as well as JADE301, an anti-IFN-β monoclonal antibody. Jade was launched based on assets licensed from Paragon Therapeutics, an antibody discovery engine founded by Fairmount. For more information, visit JadeBiosciences.com and follow the Company on LinkedIn .
In Jade Biosciences’s own words, from its job postings.
| Team | Open roles | Typical posted pay (US) |
|---|---|---|
| Ops | 3 | $175K–$190K |
Based on 3 US job postings from Jade Biosciences that disclose pay, the median posted range is $175K–$190K base salary. Ranges come straight from the job descriptions (pay-transparency disclosures), not from self-reported surveys.